Medically reviewed by Archana Sharma, DO Key Takeaways Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms.Targeted therapies, such ...

Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without ...

CAR T-cell adverse-event monitoring/management in MCL was reported suboptimal by 54%, peaking in Germany and Brazil community practices, whereas BTK inhibitor management gaps in MCL affected 30%.

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

The FDA's approval of pirtobrutinib (Jaypirca) has expanded options for patients with relapsed or refractory CLL/SLL, offering a non-covalent BTK inhibitor that can remain effective even after a ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Dr. Fritz Espedilla addresses the lack of clinical evidence for using high-dose Ivermectin to treat Stage II CLL.

Relapsed chronic lymphocytic leukemia (CLL) occurs when the cancer returns after a person has been in remission for at least 6 months. With relapsed CLL, a person may begin to experience symptoms ...